UB Paderborn / Katalog / Suche / in CDI

Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Journal of the American Heart Association, 2017-10, Vol.6 (10), p.n/a

2017

Volltextzugriff (PDF)

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Diabetes care, 2020-10, Vol.43 (10), p.2509-2518

2020

Volltextzugriff (PDF)

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)

European journal of heart failure, 2022-10, Vol.24 (10), p.1967-1977

2022

Volltextzugriff (PDF)

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Journal of the American College of Cardiology, 2017-08, Vol.70 (7), p.813-826

2017

Volltextzugriff (PDF)

Heparin-Induced Thrombocytopenia Associated with Fondaparinux

The New England journal of medicine, 2007-06, Vol.356 (25), p.2653-2655

2007

Volltextzugriff (PDF)

Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus

Diabetes research and clinical practice, 2019-06, Vol.152, p.125-134

2019

Volltextzugriff (PDF)

Physical activity in patients with stable coronary heart disease: an international perspective

European heart journal, 2013-11, Vol.34 (42), p.3286-3293

2013

Volltextzugriff (PDF)

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock

Journal of cardiac failure, 2023-07, Vol.29 (7), p.1097-1103

2023

Volltextzugriff (PDF)

Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease

International journal of cardiology, 2017-10, Vol.245, p.271-276

2017

Volltextzugriff (PDF)

The pharmacokinetics and safety of darapladib in subjects with severe renal impairment

British journal of clinical pharmacology, 2015-10, Vol.80 (4), p.654-661

2015

Volltextzugriff (PDF)

Tooth loss is independently associated with poor outcomes in stable coronary heart disease

European journal of preventive cardiology, 2016-05, Vol.23 (8), p.839-846

2016

Volltextzugriff (PDF)

THE RELATIONSHIP BETWEEN TOOTH LOSS, CARDIOVASCULAR BIOMARKERS AND OUTCOMES IN PATIENTS WITH STABLE CORONARY HEART DISEASE

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1969-1969

2016

Volltextzugriff (PDF)

A Randomized, Double‐Blind, Single‐Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants

Clinical pharmacology in drug development, 2019-04, Vol.8 (3), p.361-370

2019

Volltextzugriff (PDF)

TOOTH LOSS IS INDEPENDENTLY ASSOCIATED WITH ADVERSE OUTCOME BUT NOT MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE

Journal of the American College of Cardiology, 2015-03, Vol.65 (10), p.A1421-A1421

2015

Volltextzugriff (PDF)

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2Inhibitor, on Arterial Inflammation as Assessed With18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Journal of the American College of Cardiology, 2014-01, Vol.63 (1), p.86

2014

Volltextzugriff (PDF)

Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group

The American heart journal, 2009-12, Vol.158 (6), p.881-886.e1

2009

Volltextzugriff (PDF)

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With 18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Journal of the American College of Cardiology, 2014-01, Vol.63 (1), p.86-88

2014

Volltextzugriff (PDF)

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With18 F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Journal of the American College of Cardiology, 2014, Vol.63 (1), p.86-88

2014

Volltextzugriff (PDF)

Polymorphous ventricular tachycardia associated with normal and long Q-T intervals

The American Journal of Cardiology, 1982-06, Vol.49 (8), p.2021-2029

1982

Volltextzugriff (PDF)

Peritoneal cultures and antibiotic treatment in patients with perforated appendicitis

The European journal of surgery, 2001-03, Vol.167 (3), p.214-216

2001

Volltextzugriff (PDF)

Echocardiographic Diagnosis of Intracardiac Myxomas

Chest, 1983-07, Vol.84 (1), p.62-67

1983

Volltextzugriff (PDF)

The cardiokymography exercise test compared to the thallium-201 perfusion exercise test in the diagnosis of coronary artery disease

The American heart journal, 1984-04, Vol.107 (4), p.718-725

1984

Volltextzugriff (PDF)

Peritoneal Cultures and Antibiotic Treatment in Patients with Perforated Appendicitis

The European journal of surgery, 2001-03, Vol.167 (3), p.214-216

Dror Soffer, Shiry Zait, Joseph Klausner, Yoram Kluger

2001

Volltextzugriff (PDF)

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Journal of the American College of Cardiology, 2018-01, Vol.71 (2), p.177-192

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial

Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial

Safety and efficacy of istaroxime in patients with acute heart failure‐related pre‐cardiogenic shock – a multicentre, randomized, double‐blind, placebo‐controlled, parallel group study (SEISMiC)

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease

Heparin-Induced Thrombocytopenia Associated with Fondaparinux

Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus

Physical activity in patients with stable coronary heart disease: an international perspective

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock

Near-Normoglycemia, with Meaningful Discontinuations of Prandial Insulin, by Adding Weekly Albiglutide (Albi) to Uncontrolled Basal/Bolus Insulin-Treated Type 2 Diabetes (T2DM)

Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease

The pharmacokinetics and safety of darapladib in subjects with severe renal impairment

Tooth loss is independently associated with poor outcomes in stable coronary heart disease

THE RELATIONSHIP BETWEEN TOOTH LOSS, CARDIOVASCULAR BIOMARKERS AND OUTCOMES IN PATIENTS WITH STABLE CORONARY HEART DISEASE

A Randomized, Double‐Blind, Single‐Dose, Crossover Study to Demonstrate the Bioequivalence of 2 Formulations of Albiglutide in Healthy Adult Participants

TOOTH LOSS IS INDEPENDENTLY ASSOCIATED WITH ADVERSE OUTCOME BUT NOT MYOCARDIAL INFARCTION IN PATIENTS WITH CHRONIC CORONARY HEART DISEASE

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2Inhibitor, on Arterial Inflammation as Assessed With18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the Academic Bleeding Consensus (ABC) Multidisciplinary Working Group

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With 18F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Effect of Treatment for 12 Weeks With Rilapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, on Arterial Inflammation as Assessed With18 F-Fluorodeoxyglucose-Positron Emission Tomography Imaging

Polymorphous ventricular tachycardia associated with normal and long Q-T intervals

Peritoneal cultures and antibiotic treatment in patients with perforated appendicitis

Echocardiographic Diagnosis of Intracardiac Myxomas

The cardiokymography exercise test compared to the thallium-201 perfusion exercise test in the diagnosis of coronary artery disease

Peritoneal Cultures and Antibiotic Treatment in Patients with Perforated Appendicitis

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Suchergebnisse filtern